{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T20:57:46Z","timestamp":1790456266104,"version":"4.1.0"},"reference-count":26,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Risperidone-related metabolic side effects in children have been primarily linked to variations between guideline-recommended and clinical treatment procedures. We explored the metabolic effects of risperidone administration in pediatric patients diagnosed with neurological disorders, thus evaluating its influence on metabolic indicators. Methods: This prospective cohort study gathered data from electronic health records, medical databases, and clinical reports. These data included patient demographics (e.g., age, sex, and body mass index) and information on risperidone use, including dosage, dosing frequency, and treatment duration. Additionally, laboratory tests were conducted at baseline and during treatment, along with other pertinent clinical variables. Result: A total of 52 eligible children (male; 73.1%) with neurological disorders treated with risperidone were included. The mean age was 13.4 \u00b1 2.2 years. Risperidone was administered to 32.7% of patients for &lt;2 years, 40.4% for 2\u20135 years, and 26.9% for 6\u20139 years, with a mean duration of 3.6 years. Most (53.8%) of the children experienced at least one metabolic side effect, with hyperlipidemia being the most common (34.6%). The median prolactin level increased slightly from 448.5 ng\/mL at baseline to 479 ng\/mL after 6\u20138 weeks. No significant associations were found between age, sex, duration of treatment, dosage form, dosing frequency, and hemoglobin A1c levels. Conclusion: Monitoring metabolic and anthropometric parameters in children receiving risperidone for neurological disorders is cardinal. Clinicians should consider individualized treatment plans, closely monitor metabolic markers, and address potential risks associated with long-term risperidone use in this vulnerable population.<\/jats:p>","DOI":"10.3390\/jcm13185565","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T09:23:04Z","timestamp":1726737784000},"page":"5565","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Metabolic Side Effects of Risperidone in Pediatric Patients with Neurological Disorders: A Prospective Cohort Study"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3735-9274","authenticated-orcid":false,"given":"Jawza F.","family":"Alsabhan","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh 11322, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nouf Backer","family":"Al Backer","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, King Saud University Medical City, College of Medicine, King Saud University, Riyadh 11375, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatimah M.","family":"Hassan","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh 11322, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2921-3491","authenticated-orcid":false,"given":"Awatif B.","family":"Albaker","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11322, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghadeer","family":"Assiry","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, King Saud University Medical City, College of Medicine, King Saud University, Riyadh 11375, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11940-022-00708-5","article-title":"Treatment Approaches for Functional Neurological Disorders in Children","volume":"24","author":"Vassilopoulos","year":"2022","journal-title":"Curr. Treat. Options Neurol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.24911\/SJP.106-1588669565","article-title":"Neurological diseases at the Pediatric Neurology Clinic in a semi-urban Nigerian tertiary hospital","volume":"22","author":"Akodu","year":"2022","journal-title":"Sudan. J. Paediatr."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1055\/s-0036-1592107","article-title":"Management of the Pediatric Neurocritical Care Patient","volume":"36","author":"Horvat","year":"2016","journal-title":"Semin. Neurol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00702-022-02485-6","article-title":"Therapeutic drug monitoring in children and adolescents with schizophrenia and other psychotic disorders using risperidone","volume":"129","author":"Taurines","year":"2022","journal-title":"J. Neural Transm."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1177\/00048674211009620","article-title":"Monitoring of metabolic side-effects in children and adolescents prescribed antipsychotic medication: A systematic review","volume":"55","author":"Mead","year":"2021","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"ref_6","first-page":"575","article-title":"Management Recommendations for Metabolic Complications Associated with Second Generation Antipsychotic Use in Children and Youth Pringsheim for the CAMESA guideline group The Canadian Alliance for Monitoring Effectiveness and Safety of Antipsychotics in Children (CAMESA) Guideline Project","volume":"16","author":"Ho","year":"2011","journal-title":"Paediatr. Child. Health"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1542\/peds.2011-0855","article-title":"Antipsychotic medication use among children and risk of diabetes mellitus","volume":"128","author":"Andrade","year":"2011","journal-title":"Pediatrics"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jaac.2016.02.016","article-title":"Weight Gain and Metabolic Consequences of Risperidone in Young Children with Autism Spectrum Disorder","volume":"55","author":"Scahill","year":"2016","journal-title":"J. Am. Acad. Child. Adolesc. Psychiatry"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1177\/070674371506001005","article-title":"Increased Risk of Obesity and Metabolic Dysregulation Following 12 Months of Second-Generation Antipsychotic Treatment in Children: A Prospective Cohort Study","volume":"60","author":"Ronsley","year":"2015","journal-title":"Can. J. Psychiatry"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1089\/cap.2008.0120","article-title":"Antipsychotic Medication in Children and Adolescents: A Descriptive Review of the Effects on Prolactin Level and Associated Side Effects","volume":"19","author":"Roke","year":"2009","journal-title":"J. Child. Adolesc. Psychopharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.biopsych.2006.02.032","article-title":"Effects of Short- and Long-Term Risperidone Treatment on Prolactin Levels in Children with Autism","volume":"61","author":"Anderson","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1089\/cap.2004.14.350","article-title":"A Prospective Study of Hyperprolactinemia in Children and Adolescents Treated with Atypical Antipsychotic Agents","volume":"14","author":"Saito","year":"2004","journal-title":"J. Child. Adolesc. Psychopharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e20202484","DOI":"10.1084\/jem.20202484","article-title":"The atypical antipsychotic risperidone targets hypothalamic melanocortin 4 receptors to cause weight gain","volume":"218","author":"Li","year":"2021","journal-title":"J. Exp. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/cns.13281","article-title":"Risperidone stimulates food intake and induces body weight gain via the hypothalamic arcuate nucleus 5-HT2c receptor\u2014NPY pathway","volume":"26","author":"Wan","year":"2020","journal-title":"CNS Neurosci. Ther."},{"key":"ref_15","first-page":"S26","article-title":"Antipsychotic-Induced Changes in Blood Levels of Leptin in Schizophrenia: A Meta-Analysis","volume":"60","author":"Potvin","year":"2015","journal-title":"Can. J. Psychiatry"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.npbr.2011.02.004","article-title":"Risperidone and serum lipid profile changes in child and adolescent patients","volume":"17","author":"Karaman","year":"2011","journal-title":"Neurol. Psychiatry Brain Res."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Tsai, H.P., Hou, P.H., Mao, F.C., Chang, C.C., Yang, W.C., Wu, C.F., Liao, H.J., Lin, T.C., Chou, L.S., and Hsiao, L.W. (2021). Risperidone Exacerbates Glucose Intolerance, Nonalcoholic Fatty Liver Disease, and Renal Impairment in Obese Mice. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22010409"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"969182","DOI":"10.1155\/2015\/969182","article-title":"An overview of diabetes management in schizophrenia patients: Office based strategies for primary care practitioners and endocrinologists","volume":"2015","author":"Annamalai","year":"2015","journal-title":"Int. J. Endocrinol."},{"key":"ref_19","first-page":"55","article-title":"Review of risperidone for the treatment of pediatric and adolescent bipolar disorder and schizophrenia","volume":"4","author":"Bishop","year":"2008","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_20","unstructured":"(2023, October 08). American Diabetic Association. Available online: https:\/\/diabetes.org\/about-diabetes\/diagnosis."},{"key":"ref_21","unstructured":"(2023, October 08). Available online: https:\/\/www.who.int\/data\/nutrition\/nlis\/info\/malnutrition-in-women."},{"key":"ref_22","unstructured":"(2023, October 08). The American Academy of Family Physicians. Available online: https:\/\/www.aafp.org\/pubs\/afp\/issues\/1998\/0501\/p2192.html."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1089\/cap.2008.007","article-title":"Weight Gain and Metabolic Abnormalities During Extended Risperidone Treatment in Children and Adolescents","volume":"19","author":"Calarge","year":"2009","journal-title":"J. Child. Adolesc. Psychopharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jama.2009.1549","article-title":"Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents","volume":"302","author":"Correll","year":"2009","journal-title":"JAMA"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Vanwong, N., Ngamsamut, N., Nuntamool, N., Hongkaew, Y., Sukprasong, R., Puangpetch, A., Limsila, P., and Sukasem, C. (2020). Risperidone-Induced Obesity in Children and Adolescents With Autism Spectrum Disorder: Genetic and Clinical Risk Factors. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.565074"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Stojkovic, M., Radmanovic, B., Jovanovic, M., Janjic, V., Muric, N., and Ristic, D.I. (2022). Risperidone Induced Hyperprolactinemia: From Basic to Clinical Studies. Front. Psychiatry, 13.","DOI":"10.3389\/fpsyt.2022.874705"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/18\/5565\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:59:44Z","timestamp":1760111984000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/18\/5565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,19]]},"references-count":26,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["jcm13185565"],"URL":"https:\/\/doi.org\/10.3390\/jcm13185565","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,19]]}}}